The tetracycline part of the anthracycline antibiotics can be considered as a derivative of the anthraquinone molecule. Some of the substituted anthraquinones,especially some substituted naphthazarins such as alkannin and shikonin have antitumor activity (Paull et al.J.Med. Chem. 19,337, 1975 ,Sankawa et al.Chem.Pharm. Bul125,2392 ,1977 . As a result of trying experiences to make comple xes containing both the cisplatin and adriamycin moieties,we thought to be advisable to synthesize coordination compounds containing naphthazarine instead of tetracycline. The structure of the main compound we tested is confirmed by analytical methods and by IR and NMR spectra. It is a crystalline black solid with the stoichiometry Pt2(CIoH404) (NH3!Cl2,stable in air,soluble in DMF and DMSO but insoluble in water and most of the common organic solvents. It is planar with 2 inequivalent Pt-O bonds.The naphthazarinato ligand brings two platinum centers in an end-to-end fashion. The diplatinum complex was tested against leukemia L1210.Ehrlich ascites tumor,adenocarcinoma AC-755,1eukemia P388 and melanoma B16.Comparative work has been done with cisplatin and the ligand The LD 5 (15 days) is 60mg/kg ip. The complex " 0 has against all the above tumors activity comparable with that of cisplatin. The nephrotoxicity of the complex is much more lower than that of cisplatin.Also gastrointestinal toxicity is lowen.
Theagenion Cancer Institute,Chemotherapy Department,Thessaloniki ,Greece The c-HUS consists of thrombocytopeaia, microangiopathic hemolytic anemia and progressive renal failure~ with a mortality rate of 80% within 12 months from estblishment of the diagnosis. In general, this entity develops in patients whose tumors are either in a complete or partial remission after mitomycin-C chemotherapy. High levels of cIC with substantial platelat aggregatory activity are normally present in the sera.-A clinical study was started to prove the therapeutical benefits of SPA-immunadsorption in both groups of patients and to investigate the possible mechanisms of immunmodulstian after protein A treatment. So far 4 patients with c-HUS and 2 patients with colon cancer entered the study. The two colon cancer patients had advanced local recurrence of the disease and in one case there were additional puBmonary metastases. Both patients did not respond to a chemotherapy trial with sequential MTX/ 5-FU: -The treatment procedure consists of bi-waekly SPA-immunadsorplions of 3o~-4o% of the plasma volume, followed by the same chemotherapy regimen the patients got before recurrence. Adsorption capacity for IgG of the 200 ml-columns used was 25 mg/ml gel. Both patients had positive IC levels which dropped to normal levels after the treatment. There was an impressive hemorrhagic necrosis of tumor mass leading to partial res-r ponse. The treatment is continued at the present time.-Patients with c-HUS represamtad with decreased complement levels: suggesting am ongoing inflammatory process. In 4/4 patients a dramatic hematologic improvamont occurred: with fall in serum LDH~ rise in haptoglobin: platelats~follawad by rise of hematocrit and complement levels. The circulating IC disappeared. There was a stabilisaticn of renal impairment.-The median symptom free survival time is now 17,3 months. Oo average, response was achieved after 5 treatments over a period of lo-14 days.
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